| Literature DB >> 29385740 |
Mohammad Rezaei1,2, AliReza Moradi3,4, Mehdi Tehrani-Doost5, HamidReza Hassanabadi6, Reza Khosroabadi7.
Abstract
Abstract: The purpose of this study was to investigate the effects of combined risperidone (RIS) and pivotal response treatment (PRT) on children with autism spectrum disorder (ASD). A total of 34 children diagnosed with ASD according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) (mean age of 12.36 years) were randomly assigned to either of two groups; the first group (n = 17) received combined PRT-RIS while the second group (n = 17) received RIS only. Behavioral problems were evaluated with the Aberrant Behavior Checklist (ABC), whereas global improvement (GI) was measured with the Clinical Global Impressions (CGI). Assessment of ABC was performed before intervention, after intervention (12 weeks), and following 3 months of the intervention (follow-up). Total ABC scores were seen to decrease in both groups after 3 months, as compared with the scores prior to the interventions. Also, in both groups, mean scores of behavioral problems after the intervention were not significantly different from those prior to the intervention, in all subscales but the inappropriate speech (p < 0.001). However, both groups showed significant differences in mean scores of ABC subscales in both of the post-intervention evaluation stages. It was concluded that the combination of behavioral and drug interventions can further improve behavioral problems, ultimately improving patient's communication and social skills.Entities:
Keywords: autism spectrum disorder; behavioral therapy; medication
Year: 2018 PMID: 29385740 PMCID: PMC5835988 DOI: 10.3390/children5020019
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Descriptions for fidelity of implementation. Adapted from [1].
| The speech/language pathologists (SLP) must attract child’s attention before provoking a chance. |
| The question/education/opportunity to respond must be clear and suitable for the task. |
| The SLP should follow the child’s choice with tasks and actions. If child is not showing interest in the present task, SLP should effort to alter the practice. |
| The SLP should combine tasks the child can already complete with new tasks. |
| Reinforcement must be depending on child’s behavior. The SLP’s response must be contingent upon the child’s response. |
| Reinforcement should be natural or right associated to the favorite behavior. |
| Any target-directed effort to respond to questions, guidelines, or chances should be reinforced. |
Baseline Characteristics.
| Variable | RIS Group ( | PRT + RIS Group ( | |
|---|---|---|---|
| Age | 148.94 ± 29.41 | 144.70 ± 37.58 | 0.911 |
| MLU | 3.54 ± 0.60 | 3.23 ± 0.80 | 0.212 |
| Age of onset | 28.72 ± 4.21 | 29.68 ± 5.80 | 0.588 |
| Weight | 44.35 ± 12.31 | 43.82 ± 14.93 | 0.799 |
| Irritability | 2.72 ± 23.23 | 4.86 ± 23.05 | 0.897 |
| Lethargy/social withdrawal | 5.16 ± 30.41 | 28.52 ± 5.00 | 0.288 |
| Hyperactivity/noncompliance | 8.65 ± 22.94 | 8.75 ± 19.58 | 0.27 |
| Stereotypic behavior | 3.05 ± 17.23 | 4.45 ± 15.05 | 0.107 |
| Inappropriate speech | 1.76 ± 9.00 | 1.67 ± 9.94 | 0.285 |
RIS: Risperidone; PRT: pivotal response treatment; SD: standard deviation; MLU: Mean Length of Utterance.
MLU and ABC subscale scores for RIS and RIS plus PRT groups after treatment.
| Variable | RIS Group ( | PRT + RIS Group ( | Mean Difference | |
|---|---|---|---|---|
| MLU | 0.591 ± 3.60 | 0.832 ± 4.23 | 0.930 | ≤0.0001 |
| Irritability | 2.10 ± 13.76 | 4.80 ± 13.41 | 0.247 | 0.806 |
| Lethargy/social withdrawal | 4.84 ± 26.94 | 6.49 ± 20.88 | 4.299 | 0.001 |
| Hyperactivity/noncompliance | 6.39 ± 14.64 | 6.05 ± 12.88 | 0.431 | 0.631 |
| Stereotypic behavior | 2.34 ± 9.41 | 4.52 ± 8.05 | 0.002 | 0.999 |
| Inappropriate speech | 5.171 ± 94 | 4.471 ± 84 | 1.514 | 0.001 |
ABC: Aberrant Behavior Checklist.
Mean ± SD of the Two Treatment Groups on the Subscales of ABC at phase three.
| Variable | Baseline | Endpoint | Follow-Up | |
|---|---|---|---|---|
| RIS | 2.72 ± 23.23 | 2.10 ± 13.76 | 1.39 ± 17.76 | ≤0.0001 |
| RIS + PRT | 23.05 ± 4.86 | 13.41 ± 4.80 | 16.82 ± 4.27 | |
| RIS | 30.41 ± 5.16 | 26.94 ± 4.84 | 27.94 ± 4.86 | ≤0.0001 |
| RIS + PRT | 28.52 ± 5.00 | 20.88 ± 6.49 | 21.35 ± 5.33 | |
| RIS | 22.94 ± 8.65 | 14.46 ± 6.39 | 18.11 ± 7.00 | ≤0.0001 |
| RIS + PRT | 8.75 ± 19.58 | 6.05 ± 12.88 | 15.35 ± 6.48 | |
| RIS | 17.23 ± 3.05 | 9.41 ± 2.38 | 12.47 ± 2.06 | ≤0.0001 |
| RIS + PRT | 15/05 ± 4.45 | 8/05 ± 4.52 | 10/94 ± 4.00 | |
| RIS | 9.00 ± 1.76 | 5.17 ± 1.94 | 6.58 ± 1.87 | ≤0.0001 |
| RIS + PRT | 9.94 ± 1.67 | 4/47 ± 1.84 | 6.64 ± 1.72 |
The frequencies of adverse events in two groups.
| Variables | RIS Group ( | PRT + RIS Group ( | |
|---|---|---|---|
| Increased appetite | 4 (23.5) | 3(17.6) | 0.671 |
| Nausea | 2 (11.8) | 2(11.8) | 1 |
| Urinary problems | 3 (17.6) | 2(11.8) | 0.682 |
| Increased weight | 2 (11.8) | 2(11.8) | 1 |
| Sedation | 1 (5.9) | 1(5.9) | 1 |
| Dizziness | 1 (5.9) | 2(11.8) | 0.545 |
| Constipation | 3 (17.6) | 3(17.6) | 1 |
N (%): number (percentage).